Clinical Trial Update: An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease [Phase 3]

View source ↗

Summary

This update reports the termination of an extension of the HORIZON trial evaluating the safety of Dimebon (latrepirdine) in Huntington's disease. The study was …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• Dimebon (latrepirdine)

Snippet

Sponsor: Medivation, Inc. | Conditions: Huntington Disease | Phase 3 | Status: TERMINATED